Skip to content
2000
Volume 17, Issue 3
  • ISSN: 2589-9775
  • E-ISSN: 2589-9783

Abstract

Today's pharmaceutical products are seeing a massive increase in impurity profiling. A drug substance or product will inevitably contain contaminants in trace amounts. According to pharmaceutical chemistry, impurities are undesirable substances found in pharmaceutical compounds with therapeutic activity. Due to their extraordinary potency and likelihood of toxicity, they may exhibit unanticipated pharmacological effects that are detrimental to human health. For the pharmaceutical sector, impurity management is currently a major concern. The impurity can appear in medicines either during the formulation process or after the produced Active Pharmaceutical Ingredients (APIs) have aged. The term “impurity profiling” refers to a collection of analytical procedures that include characterizing, quantifying, and describing the known and unknown impurities found in novel pharmacological compounds. Highly sophisticated analytical techniques and instrumentation are essential for identifying small elements (drugs, contaminants, breakdown products, and metabolites) in diverse matrices. Current references and articles reveal different impurities found in the APIs of antiviral drugs, techniques for locating them, and potential countermeasures for the interferences they produce in pharmaceutical analysis. Antiviral medications are a class of medications used to treat viral infections. They work by preventing the growth of the pathogen they are intended to treat. Drugs that target viral activities must enter host cells because viruses are obligatory intracellular entities and prevent the production of viral DNA, which is subsequently converted to triphosphate. Regulatory authorities now need not just purity profiles but also impurity profiles. This review also covers the origins of impurities, how they are classified, and the different analytical techniques used to identify and quantify them. It also covers the simple, rapid, accurate, precise, and exact creation of innovative analytical techniques for determining impurity levels.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdrr/10.2174/0125899775331541250226065837
2025-03-06
2025-10-05

  • From This Site

    /content/journals/cdrr/10.2174/0125899775331541250226065837
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. VenkatesanP. ValliappanK. Impurity profiling: Theory and practice.J Pharm Sci Res201467254
     [Google Scholar]
  2. PoojashreeP. PramilaT. KumarS.M. KumarS.G.P. A review on pharmaceutical impurities and its importance in pharmacy.Am J Pharmtech Res2019976e87
     [Google Scholar]
  3. ShaikhT. Impurities characterization in pharmaceuticals: A review.SSRN39586032019Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3958603
    [Google Scholar]
  4. ShahS.R. PatelM.A. NaikM.V. PradhanP.K. UpadhyayU.M. Recent approches of” impurity profiling” in pharmaceutical analysis: A review.Int. J. Pharm. Sci. Res.20123103603
     [Google Scholar]
  5. ChandrawanshiH.K. PilaniyaK. PilaniyaU. ManchandaniP. JainP. SinghN. Recent trends in the impurity profile of pharmaceuticals.J. Adv. Pharm. Technol. Res.20101330231010.4103/0110‑5558.72422 22247862
     [Google Scholar]
  6. ICH Q3A (R2) Impurities in new drug substances - Scientific guideline | European Medicines Agency.2024Available from: https://www.ema.europa.eu/en/ich-q3a-r2-impurities-new-drug-substances-scientific-guideline [cited 2024 May 13].
  7. B BA, M KKImpurity profiling: A review.Asian J Pharma Res Deve202210213514310.22270/ajprd.v10i2.1052
     [Google Scholar]
  8. DsouzaS.J. SandeepD.S. CharyuluR.N. GowravM.P. PradeepH.K. Impurities in drug substance-an overview of ICH Q3A, Q3C and M7 guidelines.Int. J. Pharm. Investig.2024142299305[Internet].10.5530/ijpi.14.2.37
     [Google Scholar]
  9. GuidelineIHT Impurities in new drug products.Q3B R2 Curr Step2006415
     [Google Scholar]
  10. PrajapatiP. AgrawalY.K. Analysis and impurity identification in pharmaceuticals.Rev. Anal. Chem.201433212313310.1515/revac‑2014‑0001
     [Google Scholar]
  11. SaibabaS.V. KumarM.S. RamuB. Pharmaceutical impurities and their characterization: A review.Eur. J. Pharm. Med. Res.201635190196
     [Google Scholar]
  12. KarA. Pharmaceutical drug analysis.New Age International2005Available from: https://books.google.com/books?hl=en&lr=&id=nnNfLesNzLoC&oi=fnd&pg=PR7&dq=enumeration+of+impurities+in+drugs&ots=OeU6sE0GD_&sig=ZM9H_nWAwBKGyW8RztA0xmvSfQI [cited 2024 Dec 14].
     [Google Scholar]
  13. MisraB. ThakurA. MahataP.P. Pharmaceutical impurities: A review.Int. J. Pharm. Chem.201557232239
     [Google Scholar]
  14. AlsanteK.M. HatajikT.D. LohrL.L. SharpT.R. Isolation and identification of process related impurities and degradation products from pharmaceutical drug candidates, Part I.Am. Pharm. Rev.200147078
     [Google Scholar]
  15. GrodowskaK ParczewskiA Analytical methods for residual solvents determination in pharmaceutical products 2010.https://ruj.uj.edu.pl/bitstreams/e7886ef4-8d3c-492b-a0ec-76611a091394/download
  16. BhavyasriK. VishnumurthyK.M. RambabuD. SumakanthM. ICH guidelines–“Q” series (quality guidelines)-A review.GSC Biol. Pharm. Sci.201963
     [Google Scholar]
  17. SinghA. AfreenS. SinghD.P. KumarR. A review on pharmaceutical impurities and their importance.World J. Pharm. Pharm. Sci.201761013371354
     [Google Scholar]
  18. RamachandraB. Development of impurity profiling methods using modern analytical techniques.Crit. Rev. Anal. Chem.2017471243610.1080/10408347.2016.1169913 27070830
     [Google Scholar]
  19. ZhengY.Z. WangS. Advances in antifungal drug measurement by liquid chromatography-mass spectrometry.Clin. Chim. Acta201949113214510.1016/j.cca.2019.01.023 30685359
     [Google Scholar]
  20. CoveyT.R. LeeE.D. BruinsA.P. HenionJ.D. Liquid chromatography/mass spectrometry.Anal. Chem.198658141451A1461A10.1021/ac00127a001 3789400
     [Google Scholar]
  21. JainS. KumarP. VyasR.K. PanditP. DalaiA.K. Occurrence and removal of antiviral drugs in environment: A review.Water Air Soil Pollut.20132242141010.1007/s11270‑012‑1410‑3
     [Google Scholar]
  22. WatervalW.A.H. ScheijenJ.L.J.M. Ortmans-PloemenM.M.J.C. Habets-van der PoelC.D. BierauJ. Quantitative UPLC-MS/MS analysis of underivatised amino acids in body fluids is a reliable tool for the diagnosis and follow-up of patients with inborn errors of metabolism.Clin. Chim. Acta20094071-2364210.1016/j.cca.2009.06.023 19559691
     [Google Scholar]
  23. CordeiroF.C. FrancoL.L. CarvalhoT.D. BonfilioR. Impurities in active pharmaceutical ingredients and drug products: A critical review.Crit. Rev. Anal. Chem.202412110.1080/10408347.2024.2384046 39058576
     [Google Scholar]
  24. SuneethaA. KathirvelS. RamachandrikaG. A validated RP HPLC method for simultaneous estimation of lopinavir and ritonavir in combined dosage form.Int. J. Pharm. Pharm. Sci.2011314951
     [Google Scholar]
  25. KatakamP. DeyB. HwisaN.T. An experimental design approach for impurity profiling of valacyclovir-related products by RP-HPLC.Sci. Pharm.201482361763010.3797/scipharm.1403‑20 25853072
     [Google Scholar]
  26. MuralidharanS. KalaimaniJ. ParasuramanS. DhanarajS.A. Development and validation of acyclovir hplc external standard method in human plasma: Application to pharmacokinetic studies.Advances in Pharmaceutics201420141510.1155/2014/284652
     [Google Scholar]
  27. Santana-MayorÁ. Rodríguez-RamosR. Herrera-HerreraA.V. Socas-RodríguezB. Rodríguez-DelgadoM.Á. Deep eutectic solvents. The new generation of green solvents in analytical chemistry.Trends Analyt. Chem.202113411610810.1016/j.trac.2020.116108
     [Google Scholar]
  28. Kurowska-SusdorfA. ZwierżdżyńskiM. BevandaA.M. TalićS. IvankovićA. Płotka-WasylkaJ. Green analytical chemistry: Social dimension and teaching.Trends Analyt. Chem.201911118519610.1016/j.trac.2018.10.022
     [Google Scholar]
  29. GuardiaD.L.M. ArmentaS. Green analytical chemistry.Theory and practice.2010https://books.google.com/books?hl=en&lr=&id=NnTcJY2w2qMC&oi=fnd&pg=PP1&dq=%09Green+analytical+chemistry%E2%80%94theory+and+practice+-+Chemical+Society+Reviews+(RSC+Publishing)&ots=kJe4Kiohyd&sig=A0IdTrHcKV3soVUh6W33C-wnnmQ
     [Google Scholar]
  30. SharmaS. SinghN. AnkalgiA.D. RanaA. AshawatM.S. Modern trends in analytical techniques for method development and validation of pharmaceuticals: A review.J. Drug Deliv. Ther.2021111-s12113010.22270/jddt.v11i1‑s.4515
     [Google Scholar]
  31. PhadkeR. MaliR. MundheA. GosarA. Drug Impurity profiling an emerging task to Pharmaceutical Industries now days - A Review.Amer J PharmTech Res2019929411110.46624/ajptr.2019.v9.i2.010
     [Google Scholar]
  32. HamiltonR.J. SewellP.A. Introduction to high performance liquid chromatography.Introduction to high performance liquid chromatography.DordrechtSpringer Netherlands1982112[Internet].
     [Google Scholar]
  33. LoughW.J. WainerI.W. High performance liquid chromatography: Fundamental principles and practice.1995Available from: https://books.google.com/books?hl=en&lr=&id=9SzJGAmWIvMC&oi=fnd&pg=PA1&dq=%09High-Performance+Liquid+Chromatography&ots=pvOJHivtcR&sig=-JAsNAiyxaZ6tN59_mtgRL1JNFs
    [Google Scholar]
  34. XiaoW. OefnerP.J. Denaturing high-performance liquid chromatography: A review.Hum. Mutat.200117643947410.1002/humu.1130 11385705
     [Google Scholar]
  35. DebrusB. LebrunP. KindengeJ.M. Innovative high-performance liquid chromatography method development for the screening of 19 antimalarial drugs based on a generic approach, using design of experiments, independent component analysis and design space.J. Chromatogr. A20111218315205521510.1016/j.chroma.2011.05.102 21705006
     [Google Scholar]
  36. PatilM.P.N. HPLC Method Development–A Review.J Pharm Res Educ201712243260
     [Google Scholar]
  37. MuruganS. ElayarajaA. ChandrakalaK. RamaiahP. VulchiC. A review on method development and validation by using HPLC.Int. J. Novel Trends Pharm. Sci.2013347881
     [Google Scholar]
  38. PatwekarS.L. SakhareR.S. NalbalwarN.N. HPLC method development and validation-A general Concept.Int J Chem Pharm Sci201561814
     [Google Scholar]
  39. BhardwajS.K. DwivediaK. AgarwalaD.D. A review: HPLC method development and validation.Int J Anal Bioanal Chem2015547681
     [Google Scholar]
  40. KausarS. KhanS.F. Ishaq Mujeeb Ur RehmanM. A review: Mechanism of action of antiviral drugs.Int. J. Immunopathol. Pharmacol.2021352058738421100262110.1177/20587384211002621 33726557
     [Google Scholar]
  41. NirajN. MahajanS.S. PrakashA. SarmaP. MedhiB. Paxlovid.Indian J. Pharmacol.202254645245810.4103/ijp.ijp_291_22 36722557
     [Google Scholar]
  42. KhalilH.A. HassaneinN.A. El-YazbiA.F. Recent analytical methodologies for the determination of anti-covid-19 drug therapies in various matrices: A critical review.RSC Advances20231319132241323910.1039/D3RA00654A 37124020
     [Google Scholar]
  43. ImamM.S. BatubaraA.S. GamalM. AbdelazimA.H. AlmrasyA.A. RamzyS. Adjusted green HPLC determination of nirmatrelvir and ritonavir in the new FDA approved co-packaged pharmaceutical dosage using supported computational calculations.Sci. Rep.202313113710.1038/s41598‑022‑26944‑y 36599900
     [Google Scholar]
  44. RashedN.S. ZayedS. AbdelazeemA. FouadF. Development and validation of a green HPLC method for the analysis of clorsulon, albendazole, triclabendazole and ivermectin using monolithic column: Assessment of the greenness of the proposed method.Microchem. J.202015710506910.1016/j.microc.2020.105069
     [Google Scholar]
  45. JiangB. LiG. YuJ. Synthesis and crystal characteristics of nirmatrelvir.React. Chem. Eng.2023871747175910.1039/D3RE00019B
     [Google Scholar]
  46. BariS. JainP.S. ShirkhedkarA.A. SonawaneL.V. MhaskeA.J. GawadJ.B. Impurities in pharmaceuticals: A review.World J. Pharm. Res.201541029322947
     [Google Scholar]
  47. TegeliV.S. GajeliG.B. ChouguleG.K. ThoratY.S. ShivsharanU.S. KumbharS.T. Significance of impurity profiling: A Review.Int J Drug Formul Res201124174195
     [Google Scholar]
/content/journals/cdrr/10.2174/0125899775331541250226065837
Loading
Significance of Impurity Analysis in Antiviral Drug: A Critical Review
Current Drug Research Reviews 17, 394 (2025); https://doi.org/10.2174/0125899775331541250226065837
/content/journals/cdrr/10.2174/0125899775331541250226065837
/content/journals/cdrr/10.2174/0125899775331541250226065837
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): analysis; anti-viral drugs; degradation studies; Drugs; HPLC; ICH guidelines; impurity profiling; safety

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test